CA3169000A1 - Crystal of imidazopyridinone compound or salt thereof - Google Patents

Crystal of imidazopyridinone compound or salt thereof Download PDF

Info

Publication number
CA3169000A1
CA3169000A1 CA3169000A CA3169000A CA3169000A1 CA 3169000 A1 CA3169000 A1 CA 3169000A1 CA 3169000 A CA3169000 A CA 3169000A CA 3169000 A CA3169000 A CA 3169000A CA 3169000 A1 CA3169000 A1 CA 3169000A1
Authority
CA
Canada
Prior art keywords
peaks
compound
crystal
crystal form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3169000A
Other languages
English (en)
French (fr)
Inventor
Hideki Takeuchi
Yoshiro KIJIMA
Akihiro Moriyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CA3169000A1 publication Critical patent/CA3169000A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3169000A 2020-03-11 2021-03-10 Crystal of imidazopyridinone compound or salt thereof Pending CA3169000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020041453 2020-03-11
JP2020-041453 2020-03-11
PCT/JP2021/009405 WO2021182490A1 (ja) 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶

Publications (1)

Publication Number Publication Date
CA3169000A1 true CA3169000A1 (en) 2021-09-16

Family

ID=77672382

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3169000A Pending CA3169000A1 (en) 2020-03-11 2021-03-10 Crystal of imidazopyridinone compound or salt thereof

Country Status (8)

Country Link
US (1) US20230167108A1 (https=)
EP (1) EP4091670A4 (https=)
JP (1) JP7566008B2 (https=)
KR (1) KR20220152276A (https=)
CN (1) CN115279761B (https=)
AU (1) AU2021233433A1 (https=)
CA (1) CA3169000A1 (https=)
WO (1) WO2021182490A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
KR20100045480A (ko) * 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
JP2010537998A (ja) 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
CA2719234A1 (en) * 2008-05-08 2009-11-12 Joan M. Fletcher Spiroazaindoles
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
RS54010B1 (sr) * 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
CA3106385A1 (en) * 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound

Also Published As

Publication number Publication date
WO2021182490A1 (ja) 2021-09-16
EP4091670A1 (en) 2022-11-23
KR20220152276A (ko) 2022-11-15
CN115279761A (zh) 2022-11-01
JP7566008B2 (ja) 2024-10-11
US20230167108A1 (en) 2023-06-01
CN115279761B (zh) 2025-03-14
JPWO2021182490A1 (https=) 2021-09-16
AU2021233433A1 (en) 2022-10-06
EP4091670A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
CN104797581B (zh) 杂芳基炔烃化合物及其应用
KR102005068B1 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
TW202021967A (zh) 凋亡信號調節激酶１抑制劑的鹽及其晶型
WO2024051702A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
ES2831021T3 (es) Derivado de quinazolina
EP4452929A1 (en) Dhodh inhibitors containing a carboxylic acid bioisostere
ES2850023T3 (es) Compuesto de anillo heterocíclico nítrico de seis miembros sustituido con amino y preparación y uso del mismo
CN112047943A (zh) 一种选择性抑制激酶化合物及其用途
EP3487859A1 (en) ANTIMETASTATIC 2H-SELENOPHENO[3,2-h]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS
JPWO2019031471A1 (ja) 脂肪性肝疾患の治療剤及び肥満症の治療剤
CN104334528A (zh) (2-杂芳基氨基)琥珀酸衍生物
CA3169000A1 (en) Crystal of imidazopyridinone compound or salt thereof
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
JP2019504054A (ja) キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途
CN115244054B (zh) 次黄嘌呤化合物的晶体
HK40083277A (en) Crystal of imidazopyridinone compound or salt thereof
CN118724870B (zh) 蛋白降解靶向嵌合体及其应用
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
CN104321318A (zh) 4-烷酰基氨基-3-吡唑啉酮衍生物
CN110950773B (zh) 联苯二酚酰胺衍生物及其作为抗癌药物的应用
CN120208918A (zh) 芳环甲酰胺类化合物及其药物组合物和应用
WO2025016439A1 (zh) 用作cdk2/4蛋白激酶抑制剂的化合物及其应用
CA3230557A1 (en) Ep4 antagonist compound as well as salt, polymorph, and use thereof
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用
TW202539674A (zh) 用作cdk4蛋白激酶抑制劑的化合物及其應用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241213

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250523

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421